According to CoinMeta, at its third-quarter performance briefing in 2026, Botuo Biology stated that the company adheres to innovation-driven development, focusing on POCT rapid diagnosis as its main business. It continues to improve its product portfolio, accelerates registration and certification processes both domestically and internationally, and advances the development of high-end, high-quality microfluidic chip detection reagents for its microfluidic fluorescence detection platform, thereby enhancing the comprehensive competitiveness of its POCT products. At the same time, the company is actively making strategic moves in cutting-edge medical fields. By establishing industrial investment platforms for equity participation or mergers and acquisitions, and by participating in industrial funds, it explores emerging areas such as brain-computer interfaces and AI medical technologies, aiming to create long-term potential growth opportunities.